title: A case of clonally distinct relapse of Burkitt lymphoma 9 years after complete remission.
abstract: We report a case of HIV-negative Burkitt lymphoma (BL) that relapsed 9 years after complete remission. We performed a polymerase chain reaction analysis of three regions of the VDJ junction of the immunoglobulin heavy chain (IGH) gene and compared the clonality of the first and second BL lesions, which were found to be clonally distinct. The patient received the R-Hyper CVAD/R-MA regimen; however, leukoencephalopathy subsequently developed due to the effect of cytarabine, and the regimen was changed to R-IVAM. The patient achieved complete remission and received high-dose chemotherapy following autologous stem cell transplantation. He maintained the complete remission for 72 months after transplantation. Given this outcome, we suggest that clonally distinct relapse of HIV-negative BL may exhibit a good prognosis.
authors.affiliation: Division of Hematology/Oncology, Department of Internal Medicine, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1143, Japan, kojima@tokai-u.jp.
authors.forename: Minoru
authors.initials: M
authors.lastname: Kojima
authors.forename: Naoya
authors.initials: N
authors.lastname: Nakamura
authors.forename: Miharu
authors.initials: M
authors.lastname: Yabe
authors.forename: Mami
authors.initials: M
authors.lastname: Tokunaka
authors.forename: Yara Yukie
authors.initials: YY
authors.lastname: Kikuti
authors.forename: Tomoki
authors.initials: T
authors.lastname: Kikuchi
authors.forename: Hiromichi
authors.initials: H
authors.lastname: Murayama
authors.forename: Makiko
authors.initials: M
authors.lastname: Moriuchi
authors.forename: Kosuke
authors.initials: K
authors.lastname: Tsuboi
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Ogawa
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Ando
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001483:Base Sequence; D002051:Burkitt Lymphoma / Q000235:genetics* / Q000473:pathology / Q000628:therapy*; D003520:Cyclophosphamide / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D003907:Dexamethasone / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005047:Etoposide / Q000627:therapeutic use; D005803:Genes, Immunoglobulin; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007069:Ifosfamide / Q000627:therapeutic use; D007143:Immunoglobulin Heavy Chains / Q000235:genetics; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D008969:Molecular Sequence Data; D009364:Neoplasm Recurrence, Local / Q000235:genetics* / Q000473:pathology / Q000628:therapy*; D012074:Remission Induction; D060152:V(D)J Recombination; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D007143:Immunoglobulin Heavy Chains; D003561:Cytarabine; D014750:Vincristine; D005047:Etoposide; D003907:Dexamethasone; D004317:Doxorubicin; D003520:Cyclophosphamide; D007069:Ifosfamide; D008727:Methotrexate